Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer
Omnicell (NASDAQ: OMCL) has appointed Perry A. Genova, PhD as Senior Vice President and Chief Technology Officer, effective March 31, 2025. Dr. Genova brings over 25 years of experience in product development, strategic planning, and regulatory compliance across medical device, pharmaceutical, and life sciences industries.
In his new role, Dr. Genova will spearhead Omnicell's technology strategy, focusing on addressing medication and supply management challenges across care settings to advance the company's vision of the Autonomous Pharmacy. According to Executive Vice President and COO Nnamdi Njoku, Genova's entrepreneurial mindset is expected to play a important role in advancing Omnicell's multi-year, outcome-centric growth strategy.
Omnicell (NASDAQ: OMCL) ha nominato Perry A. Genova, PhD come Vicepresidente Senior e Chief Technology Officer, con effetto dal 31 marzo 2025. Il Dr. Genova porta con sé oltre 25 anni di esperienza nello sviluppo di prodotti, nella pianificazione strategica e nella conformità normativa nei settori dei dispositivi medici, farmaceutico e delle scienze della vita.
Nel suo nuovo ruolo, il Dr. Genova guiderà la strategia tecnologica di Omnicell, concentrandosi sulla risoluzione delle sfide nella gestione dei farmaci e delle forniture nei vari contesti di cura, per promuovere la visione dell'azienda della Farmacia Autonoma. Secondo il Vicepresidente Esecutivo e COO Nnamdi Njoku, la mentalità imprenditoriale di Genova dovrebbe svolgere un ruolo importante nell'avanzare la strategia di crescita a lungo termine e incentrata sui risultati di Omnicell.
Omnicell (NASDAQ: OMCL) ha nombrado a Perry A. Genova, PhD como Vicepresidente Senior y Director de Tecnología, con efecto a partir del 31 de marzo de 2025. El Dr. Genova aporta más de 25 años de experiencia en desarrollo de productos, planificación estratégica y cumplimiento normativo en las industrias de dispositivos médicos, farmacéutica y ciencias de la vida.
En su nuevo rol, el Dr. Genova liderará la estrategia tecnológica de Omnicell, enfocándose en abordar los desafíos de la gestión de medicamentos y suministros en los entornos de atención para avanzar en la visión de la empresa de la Farmacia Autónoma. Según el Vicepresidente Ejecutivo y COO Nnamdi Njoku, se espera que la mentalidad emprendedora de Genova desempeñe un papel importante en el avance de la estrategia de crecimiento centrada en resultados de varios años de Omnicell.
Omnicell (NASDAQ: OMCL)은 Perry A. Genova, PhD를 수석 부사장 겸 최고 기술 책임자로 임명하며, 2025년 3월 31일부터 효력이 발생합니다. Genova 박사는 의료기기, 제약 및 생명과학 산업 전반에 걸쳐 제품 개발, 전략적 계획 및 규제 준수 분야에서 25년 이상의 경험을 가지고 있습니다.
그의 새로운 역할에서 Genova 박사는 Omnicell의 기술 전략을 주도하며, 자율 약국이라는 회사의 비전을 발전시키기 위해 다양한 치료 환경에서 약물 및 공급 관리 문제를 해결하는 데 집중할 것입니다. Nnamdi Njoku 부사장 겸 COO에 따르면, Genova 박사의 기업가 정신은 Omnicell의 다년간의 결과 중심 성장 전략을 발전시키는 데 중요한 역할을 할 것으로 기대됩니다.
Omnicell (NASDAQ: OMCL) a nommé Perry A. Genova, PhD au poste de Vice-Président Senior et Directeur Technique, à compter du 31 mars 2025. Le Dr Genova apporte plus de 25 ans d'expérience dans le développement de produits, la planification stratégique et la conformité réglementaire dans les secteurs des dispositifs médicaux, de la pharmacie et des sciences de la vie.
Dans son nouveau rôle, le Dr Genova dirigera la stratégie technologique d'Omnicell, en se concentrant sur la résolution des défis liés à la gestion des médicaments et des fournitures dans divers contextes de soins, afin de faire avancer la vision de l'entreprise d'une pharmacie autonome. Selon Nnamdi Njoku, Vice-Président Exécutif et COO, l'esprit entrepreneurial de Genova devrait jouer un rôle clé dans l'avancement de la stratégie de croissance pluriannuelle axée sur les résultats d'Omnicell.
Omnicell (NASDAQ: OMCL) hat Perry A. Genova, PhD zum Senior Vice President und Chief Technology Officer ernannt, mit Wirkung zum 31. März 2025. Dr. Genova bringt über 25 Jahre Erfahrung in der Produktentwicklung, strategischen Planung und regulatorischen Compliance in den Bereichen Medizintechnik, Pharma und Lebenswissenschaften mit.
In seiner neuen Rolle wird Dr. Genova die Technologie-Strategie von Omnicell leiten und sich darauf konzentrieren, Herausforderungen im Bereich der Medikamenten- und Versorgungsmanagement in verschiedenen Pflegeumgebungen anzugehen, um die Vision des Unternehmens einer autonomen Apotheke voranzutreiben. Laut Nnamdi Njoku, Executive Vice President und COO, wird Genovas unternehmerische Denkweise eine wichtige Rolle bei der Umsetzung der mehrjährigen, ergebnisorientierten Wachstumsstrategie von Omnicell spielen.
- Strategic appointment of experienced technology leader with 25+ years in relevant industries
- Strengthening of executive team with expertise in product development and regulatory compliance
- None.
Medical device, pharmaceutical, and life sciences expert tapped to lead Company’s technology strategy and global engineering organization
Perry A.
In this role, Dr.
Dr.
“We believe Perry’s entrepreneurial mindset will be pivotal to advancing our multi-year, outcome-centric growth strategy as we strive to deliver clinical and operational outcomes for our customers,” said Nnamdi Njoku, executive vice president and chief operating officer at Omnicell. “His focus on building trust and collaboration among strategic partners and internal and external stakeholders will help to drive forward our purpose to transform medication management across all care settings.”
About Perry Genova
Dr.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324514095/en/
Betsy Martinelli
Director, Corporate Marketing
Betsy.Martinelli@omnicell.com
412-334-3256
Source: Omnicell, Inc.
FAQ
When will Perry Genova start as CTO at Omnicell (OMCL)?
What experience does Perry Genova bring to Omnicell (OMCL)?
What will be Perry Genova's main responsibilities at Omnicell (OMCL)?
How does this appointment align with Omnicell's (OMCL) business strategy?
